jsh-23-hcl

Description: JSH-23 HCl is designed as an inhibitor of NF-kappaB transcriptional activity with IC50 of 7.1 uM in RAW 264.7 cell line. JSH-23 inhibits NF-kappaB transcriptional activity in a dose-dependent manner in LPS-stimulated macrophages RAW 264.7. This effect is not due to its cytotoxicity. In the same condition, JSH-23 is found to significantly decrease the LPS-induced DNA binding activity of NF-kappaB while decrease nuclear amount of NF-kappaB p65. JSH-23 plays these roles without affecting IkappaB degradation. In addition, JSH-23 also shows inhibition effects on the expression of the pro-inflammatory transcripts and enzymes, including IL-6, IL-1beta, COX-2 and TNF-alpha. Furthermore, JSH-23 inhibits LPS-induced apoptotic chromatin condensation.

References: FEBS Lett. 2004 Jul 30; 571(1-3):50-4; Diabetes Obes Metab. 2011 Aug; 13(8):750-8.